<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320312447650</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320312447650</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jung</surname><given-names>Christian</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Florvaag</surname><given-names>Anna</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Oberle</surname><given-names>Volker</given-names></name>
<xref ref-type="aff" rid="aff2-1470320312447650">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fritzenwanger</surname><given-names>Michael</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kretschmar</surname><given-names>Daniel</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kuethe</surname><given-names>Friedhelm</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Betge</surname><given-names>Stefan</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Goebel</surname><given-names>Bjoern</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Franz</surname><given-names>Marcus</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barz</surname><given-names>Dagmar</given-names></name>
<xref ref-type="aff" rid="aff2-1470320312447650">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ferrari</surname><given-names>Markus</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Figulla</surname><given-names>Hans R</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312447650">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320312447650"><label>1</label>First Department of Medicine, Friedrich-Schiller-University Jena, Germany</aff>
<aff id="aff2-1470320312447650"><label>2</label>Division of Cardiology, Institute for Transfusion Medicine, Friedrich-Schiller-University Jena, Germany</aff>
<author-notes>
<corresp id="corresp1-1470320312447650">Christian Jung, Department of Medicine, Division of Cardiology, Friedrich-Schiller-University, Erlanger Allee 101, 07740 Jena, Germany. Email: <email>christian.jung@med.uni-jena.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>3</issue>
<fpage>401</fpage>
<lpage>406</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1470320312447650">
<title>Background:</title>
<p>Endothelial progenitor cells (EPCs) are known to play a significant role in reendothelialization and vascular repair. Recently, a mineralocorticoid receptor was demonstrated to be expressed by EPCs. The study aimed to evaluate a potential influence of eplerenone treatment on the total number of EPCs in patients with chronic heart failure.</p>
</sec>
<sec id="section2-1470320312447650">
<title>Methods:</title>
<p>Eighty-seven male patients with chronic heart failure were included (age: 23–83 years; body mass index 29.1 ± 5.1 kg/m<sup>2</sup>; New York Heart failure classification (NYHA) I: 29 patients, NYHA II: 32 patients, NYHA III: 26 patients). Numbers of circulating EPCs were quantified immediately using flow cytometry. Twenty-eight patients received therapy with eplerenone. Patients were further characterized by echocardiography, spirometry and laboratory markers.</p>
</sec>
<sec id="section3-1470320312447650">
<title>Results:</title>
<p>Patients with ongoing eplerenone administration showed higher levels of circulating cells expressing CD34+ (<italic>p</italic>&lt;0.05) and CD34+KDR+ (<italic>p</italic>&lt;0.05) and CD34+CD133+KDR+ cells (<italic>p</italic>&lt;0.05). The effects of eplerenone treatment could be shown to be independent of NYHA status, genesis of the underlying cardiovascular morbidity, left ventricular function and co-medication.</p>
</sec>
<sec id="section4-1470320312447650">
<title>Conclusion:</title>
<p>Patients with chronic heart failure treated with eplerenone show higher numbers of EPCs. The clinical benefit for treatment with eplerenone has been demonstrated even for patients with mild heart failure and might be partially mediated by EPCs.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Endothelial progenitor cells</kwd>
<kwd>heart failure</kwd>
<kwd>vascular diseases</kwd>
<kwd>apoptosis</kwd>
<kwd>eplerenone</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-1470320312447650" sec-type="intro">
<title>Introduction</title>
<p>Endothelial progenitor cells (EPCs) home to sites of ischaemia and vascular injury as a repair mechanism to damaged or impaired endothelium. They contribute to reendothelialization, neovascularization and normalization of endothelial function and restoration of blood flow at the site of vascular injury.<sup><xref ref-type="bibr" rid="bibr1-1470320312447650">1</xref></sup> Furthermore, several studies have demonstrated that EPCs contribute to the improvement of myocardial neovascularization and function.<sup><xref ref-type="bibr" rid="bibr2-1470320312447650">2</xref></sup> These processes are governed by a complex network of endogenous cytokines and are affected by exogenous agents such as medications. Not only an impaired function but also a reduced number of EPCs has been linked to endothelial dysfunction<sup><xref ref-type="bibr" rid="bibr3-1470320312447650">3</xref></sup> as well as increased risk for atherosclerosis and cardiovascular morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr4-1470320312447650">4</xref></sup> Besides cytokines and medications EPCs are influenced by a number of factors: physical activity increases whereas cigarette smoking reduces the number and function of EPCs. There is for example an inverse relation between EPC number and the metabolic syndrome,<sup><xref ref-type="bibr" rid="bibr5-1470320312447650">5</xref></sup> hypertension,<sup><xref ref-type="bibr" rid="bibr6-1470320312447650">6</xref></sup> family history of coronary artery disease (CAD),<sup><xref ref-type="bibr" rid="bibr7-1470320312447650">7</xref></sup> diabetes<sup><xref ref-type="bibr" rid="bibr8-1470320312447650">8</xref></sup> and hypercholesterinaemia.<sup><xref ref-type="bibr" rid="bibr9-1470320312447650">9</xref></sup></p>
<p>Recent findings from both experimental models and clinical studies indicated that the biology of EPCs is strongly related to the pathophysiology of heart failure (HF). Patients with HF irrespective of its aetiology have significantly reduced levels of circulating EPCs compared with healthy individuals.<sup><xref ref-type="bibr" rid="bibr10-1470320312447650">10</xref></sup> Furthermore, the number of EPCs, as measured by the number of CD34+ mononuclear cells, was decreased in severe HF and increased in proportion to the amelioration of HF during hospitalization.<sup><xref ref-type="bibr" rid="bibr11-1470320312447650">11</xref></sup> Nevertheless, other studies reported conflicting results regarding the levels of EPCs in patients with HF.<sup><xref ref-type="bibr" rid="bibr12-1470320312447650">12</xref><xref ref-type="bibr" rid="bibr13-1470320312447650"/>-<xref ref-type="bibr" rid="bibr14-1470320312447650">14</xref></sup> This phenomenon can be partially explained by the lack of uniform criteria to precisely define the cellular characteristics of EPCs. However, pharmacological mobilization of EPCs and intracoronary infusion of circulating progenitor cells improved left ventricular remodelling and function in pilot studies on patients with post-infarction HF.<sup><xref ref-type="bibr" rid="bibr15-1470320312447650">15</xref></sup></p>
<p>Different pharmacological and lifestyle interventions have been identified to increase number and function and decrease apoptosis of EPCs.<sup><xref ref-type="bibr" rid="bibr16-1470320312447650">16</xref></sup> Experimental and clinical studies have revealed that the number of EPCs can be increased by substances such as hormones, statins, recombinant human erythropoietin, or drugs mediating angiotensin- converting enzyme (ACE) inhibition or angiotensin II receptor antagonism.<sup><xref ref-type="bibr" rid="bibr17-1470320312447650">17</xref></sup> However, in patients with chronic heart failure only few substances have been investigated, although there is evidence that statins positively affect EPCs in patients with chronic HF.<sup><xref ref-type="bibr" rid="bibr18-1470320312447650">18</xref></sup></p>
<p>Recently, Thum et al. demonstrated an expression of a mineralocorticoid receptor on EPCs. Treatment of human EPCs with aldosterone impaired function of EPCs, such as differentiation, migration and proliferation in vitro.<sup><xref ref-type="bibr" rid="bibr19-1470320312447650">19</xref></sup> Impaired EPC function was rescued by pharmacological blockade or genetic ablation of the mineralocorticoid receptor (MR). In addition, EPCs from patients with primary hyperaldosteronism compared with controls of similar age displayed reduced migratory potential and endothelial dysfunction.</p>
<p>It is now well documented that the addition of the selective mineralocorticoid receptor antagonist eplerenone to standard evidence-based therapy reduces the risk of death and hospitalization in patients with different stages of HF.<sup><xref ref-type="bibr" rid="bibr20-1470320312447650">20</xref></sup> Eplerenone mediates its effects by antagonizing the action of aldosterone at the MR. An elevated aldosterone level is documented in patients with HF, and conventional therapies, such as ACE inhibitors, angiotensin-receptor blockers and β-blockers, do not act on the MR. Since it has been documented that hyperaldosteronism is associated with a decrease in EPC numbers in rats<sup><xref ref-type="bibr" rid="bibr21-1470320312447650">21</xref></sup> we hypothesized that eplerenone treatment is associated with increased EPC numbers in HF patients.</p>
</sec>
<sec id="section6-1470320312447650" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section7-1470320312447650">
<title>Study subjects</title>
<p>The study was approved by the local ethical committee. Eighty-seven patients were enrolled into the study after giving their written informed consent. The study complies with the Declaration of Helsinki. All patients were recruited consecutively in our university referral outpatient clinics for patients with chronic HF. Patients were included irrespectively of their HF genesis. Medical history including cardiovascular risk factors, previous and present cardiovascular events, current drug treatment and vital signs was obtained from a personal interview. Patients with acute coronary syndromes within the last three months were excluded from the study. Furthermore, only patients with stable conditions were included in the study. This was defined by no history of decompensated HF within the last three months and no change of more than one New York Heart failure classification (NYHA) class in clinical presentation. In addition, no patients in NYHA class IV were included. Further exclusion criteria were clinical or biochemical evidence for the presence of a systemic inflammatory disease, terminal renal insufficiency (serum creatinine &gt;250mmol/L), malignant diseases, thrombocytopenia (&lt;100,000/μl) or anaemia (haemoglobin &lt;10.0 g/dl). Diabetes was assessed determination of fasting blood glucose (&gt;6.0 mmol/L) and/or by personal medical history and an elevation of HbA1c above 5.3%. Patients with spironolactone were excluded from this study. Only male patients were included in order to avoid sexual differences in mineralocorticoid metabolism.</p>
</sec>
<sec id="section8-1470320312447650">
<title>Echocardiography</title>
<p>The echocardiograms (Philipps iE33, Philipps, Germany) were performed by cardiologists not related to this study and unaware of the blood testing results. Left ventricular ejection fraction (LV EF%) was derived using Simpson’s modified biplane method; left ventricular end-diastolic diameter (LVEDD) was measured in parasternal long axis.</p>
</sec>
<sec id="section9-1470320312447650">
<title>Electrocardiogram and laboratory investigations</title>
<p>The recording of the electrocardiogram and the determination of blood lipids, creatinine and red blood cell count, as well as brain natriuretic peptide (BNP), were done according to internal and international standards.</p>
</sec>
<sec id="section10-1470320312447650">
<title>Circulating EPC number</title>
<p>A venous blood sample (10ml) was obtained in EDTA tubes for enumeration of EPCs. Different subpopulations were identified by using the haematopoietic progenitor cell marker CD34, the immature haematopoietic progenitor cell marker CD133 and the endothelial cell receptor VEGFR2 (vascular endothelial growth factor receptor-2, also known as kinase domain receptor, KDR), as described previously.<sup><xref ref-type="bibr" rid="bibr22-1470320312447650">22</xref>,<xref ref-type="bibr" rid="bibr23-1470320312447650">23</xref></sup> Briefly, peripheral blood mononuclear cells (PBMCs) were incubated with allophycocyanin (APC)-conjugated anti-human CD34 monoclonal antibody (mAb) (BD Biosciences), phycoerythrin (PE)-conjugated anti-human CD133 mAb (Milteny Biotec) and fluoresceinisothiocyanate-conjugated monoclonal anti-VEGFR2 (R&amp;D Systems) for 60 min at +4°C. Control isotype immunoglobulin antibodies were obtained from Becton Dickinson. The cytometer (FACScalibur, BD Biosciences, Franklin Lakes, NJ, USA) acquired at least 5 × 10<sup>6</sup> events. The frequency of peripheral blood cells positive for these reagents was determined by a two-dimensional side-scatter fluorescence dot-plot analysis of the samples, after appropriate gating. Data were processed using the Summit software program (BD CellQuest Pro, Version 5.2.1).</p>
</sec>
<sec id="section11-1470320312447650">
<title>Statistical analyses</title>
<p>All data are expressed as mean ± standard deviation (SD). Continuous variables were tested for normal distribution with the Kolmogorov–Smirnov test. Non-normally distributed continuous variables groups were compared by the Mann–Whitney <italic>U</italic> test, while others were analysed by <italic>t</italic> test (two-sided, including Levene’s test for equality of variances). Bivariate correlation (Spearman’s rank correlation coefficient) was used to correlate circulating EPC counts with risk factors or drug treatment. Statistical significance was assumed if a null hypothesis could be rejected at <italic>p</italic>≤0.05. All statistical analyses were performed with IBM SPSS statistics, version 19.0 (IBM Inc.).</p>
</sec>
</sec>
<sec id="section12-1470320312447650" sec-type="results">
<title>Results</title>
<p>The baseline characteristics of the 87 subjects are summarized in <xref ref-type="table" rid="table1-1470320312447650">Table 1</xref>. Patients were divided into two groups according to their current eplerenone treatment status. The two groups were well matched for age, anthropometric indices, comorbidities and co-medication. Furthermore, there was no significant difference in the genesis of HF and in echocardiographic and laboratory findings (<xref ref-type="table" rid="table2-1470320312447650">Table 2</xref>). Furthermore, there was no significant difference in exercise capacity as measured in the maximally achieved power stage (124 ± 46 Watt versus 125 ± 55 Watt, <italic>p</italic>=0.94), nor in maximum oxygen uptake (19.3 ± 5.0 ml/kg per min versus 21.4 ± 6.1 ml/kg per min, <italic>p</italic>=0.36).</p>
<table-wrap id="table1-1470320312447650" position="float">
<label>Table 1.</label>
<caption><p>Baseline characteristics of the study population. Patients were grouped according to their ongoing therapy with eplerenone.</p></caption>
<graphic alternate-form-of="table1-1470320312447650" xlink:href="10.1177_1470320312447650-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Patients without eplerenone</th>
<th align="left">Patients with eplerenone</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>N</italic></td>
<td>59</td>
<td>28</td>
<td/>
</tr>
<tr>
<td colspan="4">Patient characteristics</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62 ± 13</td>
<td>58 ± 15</td>
<td>n.s.</td>
</tr>
<tr>
<td><bold>Body weight (kg)</bold></td>
<td>90 ± 18</td>
<td>91 ± 18</td>
<td>n.s.</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>29 ± 5</td>
<td>30 ± 6</td>
<td>n.s.</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>133 ± 24</td>
<td>133 ± 17</td>
<td>n.s.</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>84 ± 15</td>
<td>83 ± 12</td>
<td>n.s.</td>
</tr>
<tr>
<td colspan="4">Comorbidities (<italic>n</italic> (%))</td>
</tr>
<tr>
<td>Hypertension</td>
<td>43 (72)</td>
<td>22 (78)</td>
<td>n.s.</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>23 (39)</td>
<td>15 (51)</td>
<td>n.s.</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>27 (46)</td>
<td>17 (60</td>
<td>n.s.</td>
</tr>
<tr>
<td>Diabetes</td>
<td>17 (29)</td>
<td>9 (32)</td>
<td>n.s.</td>
</tr>
<tr>
<td colspan="4">Co-medication (<italic>n</italic> (%))</td>
</tr>
<tr>
<td>Statin</td>
<td>27 (46)</td>
<td>16 (57)</td>
<td>n.s.</td>
</tr>
<tr>
<td>ACE inhibitor</td>
<td>49 (83)</td>
<td>22 (79)</td>
<td>n.s.</td>
</tr>
<tr>
<td>Betablocker</td>
<td>55 (93)</td>
<td>28 (100)</td>
<td>n.s.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320312447650">
<p>BMI: body mass index; ACE: angiotensin-converting enzyme; n.s.: not significant</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1470320312447650" position="float">
<label>Table 2.</label>
<caption><p>Characteristics of the study population regarding their heart failure, echocardiographic results, exercise capacity and laboratory values.</p></caption>
<graphic alternate-form-of="table2-1470320312447650" xlink:href="10.1177_1470320312447650-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Patients without eplerenone</th>
<th align="left">Patients with eplerenone</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Heart failure characteristics (<italic>n</italic> (%))</td>
</tr>
<tr>
<td>NYHA classification I</td>
<td>21 (36)</td>
<td>8 (28)</td>
<td>n.s.</td>
</tr>
<tr>
<td>NYHA classification II</td>
<td>22 (37)</td>
<td>10 (36)</td>
<td/>
</tr>
<tr>
<td>NYHA classification III</td>
<td>16 (27)</td>
<td>10 (36)</td>
<td/>
</tr>
<tr>
<td>Heart failure genesis</td>
<td/>
<td/>
<td>n.s.</td>
</tr>
<tr>
<td><bold>Ischaemic cardiomyopathy</bold></td>
<td>19 (32)</td>
<td>10 (36)</td>
<td/>
</tr>
<tr>
<td>Dilatative cardiomyopathy</td>
<td>21 (36)</td>
<td>7 (25)</td>
<td/>
</tr>
<tr>
<td>Hypertensive cardiomyopathy</td>
<td>11 (19)</td>
<td>10 (36)</td>
<td/>
</tr>
<tr>
<td>Other genesis</td>
<td>8 (14)</td>
<td>1 (4)</td>
<td/>
</tr>
<tr>
<td colspan="4">Echocardiographic parameters</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>38 ± 14</td>
<td>37 ± 10</td>
<td>n.s.</td>
</tr>
<tr>
<td>LVEDD (mm)</td>
<td>57.1 ± 8.7</td>
<td>57.1 ± 6.6</td>
<td>n.s.</td>
</tr>
<tr>
<td>IVSd (mm)</td>
<td>10.9 ± 2.8</td>
<td>11.4 ± 2.9</td>
<td>n.s.</td>
</tr>
<tr>
<td>PAP (mmHg + CVP)</td>
<td>26 ±11</td>
<td>25 ± 8</td>
<td>n.s.</td>
</tr>
<tr>
<td colspan="4">Laboratory values</td>
</tr>
<tr>
<td>Creatinine (mmol/L)</td>
<td>128 ± 100</td>
<td>107 ± 30</td>
<td>n.s.</td>
</tr>
<tr>
<td>Cholesterin (mmol/L)</td>
<td>5.1 ± 1.4</td>
<td>5.0 ± 1.6</td>
<td>n.s.</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>2.9 ± 1.2</td>
<td>3.1 ± 1.2</td>
<td>n.s.</td>
</tr>
<tr>
<td>BNP (pg/ml)</td>
<td>572 ± 515</td>
<td>563 ± 593</td>
<td>n.s.</td>
</tr>
<tr>
<td>Haemoglobin (g/dl)</td>
<td>14.0 ± 2.0</td>
<td>14.0 ± 2.1</td>
<td>n.s.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1470320312447650">
<p>NYHA: New York Heart failure classification; LVEDD: left ventricular end-diastolic diameter; IVSd: intraventricular septum, diastolic; PAP: pulmonal arterial pressure; CVP: central venous pressure; LDL: low density lipoprotein; BNP: brain natriuretic peptide; n.s.: not significant</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Comparing the different EPC subpopulations there were significant differences between patients treated with eplerenone for CD34+ (<italic>p</italic>=0.013, <xref ref-type="fig" rid="fig1-1470320312447650">Figure 1</xref>), CD34+CD133+ (<italic>p</italic>=0.045), as well as CD34+CD133+KDR+ (<italic>p</italic>=0.019).</p>
<fig id="fig1-1470320312447650" position="float">
<label>Figure 1.</label>
<caption><p>Endothelial progenitor cell subpopulations detected in patients with chronic heart failure divided according to their current eplerenone treatment status. Shown are CD34+ (upper left), CD34+CD133+ (upper right), CD34+KDR+ (lower left) and CD34+CD133+KDR+ (lower right) subpopulations.</p>
<p>*Significant at <italic>p</italic>&lt;0.05 level.</p></caption>
<graphic xlink:href="10.1177_1470320312447650-fig1.tif"/>
</fig>
<p>If the cohort was split according to the NYHA classification and the comparisons made regarding eplerenone treatment, significant differences could be observed in the NYHA I group for CD34+ (<italic>p</italic>=0.027), CD34+CD133+ (<italic>p</italic>=0.030), CD34 +KDR+ (<italic>p</italic>=0.011) cells. There were no significant differences in the NYHA II group. In addition, CD34+CD133+KDR+ differed in the NYHA III group (<italic>p</italic>=0.026). However, there was no difference regarding the different EPC subpopulations if the patients were grouped for their HF aetiology.</p>
<p>There was no further influence on EPCs if coronary artery disease was present. Furthermore, there was no difference between patients with and without diabetes. In addition no association to the smoking status and the use of other medications, including statins and ACE-inhibitors, could be detected. However, patients overweight as defined by a body mass index (BMI) &gt;30kg/m<sup>2</sup> had higher CD34+ (<italic>p</italic>=0.044) and higher CD34+CD133+ cell counts (<italic>p</italic>=0.002).</p>
<p>There were no significant correlations between laboratory findings and exercise capacity in the whole cohort. However, analysing the cohort separated according to HF aetiology, there is in patients with ischaemic cardiomyopathy a strong association between CD34+ cells and exercise capacity (<italic>p</italic>=0.039, <italic>R</italic><sup>2</sup>: 0.576) and a negative correlation to BNP values (<italic>p</italic>=0.033, <italic>R</italic><sup>2</sup>: −0.435). Such associations could not be detected in the other aetiology cohorts.</p>
</sec>
<sec id="section13-1470320312447650" sec-type="discussion">
<title>Discussion</title>
<p>The main finding of the present observational study is a positive effect of eplerenone treatment on the number of EPCs in patients with congestive heart failure (CHF). The benefit of eplerenone treatment on hard clinical endpoints has been extensively demonstrated. The protective mechanisms are poorly understood, but it has been hypothesized that an activation of the MR by both aldosterone and cortisol plays an important role in the pathophysiology of HF and MRs are overexpressed in the failing heart.<sup><xref ref-type="bibr" rid="bibr24-1470320312447650">24</xref></sup> Activation of the MR has been shown to promote cardiac fibrosis in experimental models, and in patients with HF, as well as in patients after myocardial infarction, the use of MR antagonists decreases extracellular-matrix turnover, as assessed by measuring serum levels of collagen biomarkers.<sup><xref ref-type="bibr" rid="bibr25-1470320312447650">25</xref></sup> Thus, a so-called reverse tissue remodelling with a resulting improvement of cardiac function might be initiated.</p>
<p>Experimental and clinical studies suggest that MR antagonists favourably affect several other important mechanisms known to have a role in the progression of HF.<sup><xref ref-type="bibr" rid="bibr20-1470320312447650">20</xref></sup></p>
<p>However, no human study has investigated the effects on EPCs, a cell population that has been associated with endothelial regeneration and improved cardiovascular outcome. In vitro studies revealed an expression of a MR on EPCs and impaired EPC function following aldosterone treatment. In addition, impaired EPC function could be restored by pharmacological blockade or genetic ablation of the MR. Kobayashi et al. found a positive effect of eplerenone treatment on EPC in an animal model of hindlimb ischaemia.<sup><xref ref-type="bibr" rid="bibr26-1470320312447650">26</xref></sup> Therefore, the current study adds to the body of knowledge that this effect has clinical relevance and that an increased number of EPCs might functionally contribute to the positive effect of eplerenone treatment in patients with CHF. The prognostic impact of EPC levels has been confirmed in a large study in patients with CHF, in which they were demonstrated to be the most important determinant of prognosis with advanced age and diabetes mellitus at a Cox proportional regression analysis.<sup><xref ref-type="bibr" rid="bibr27-1470320312447650">27</xref></sup> However, the relation between HF and EPC levels is complex and the existing data are conflicting. It has been demonstrated that functional NYHA class is related to different levels of CD34+ cells.<sup><xref ref-type="bibr" rid="bibr12-1470320312447650">12</xref></sup> Indeed, compared with healthy control subjects, patients in the lower functional classes (NYHA I and II) had higher levels of CD34+ cells, which, in contrast, were significantly lower in NYHA III and IV patients. These lower levels of EPCs were interpreted to be related to the higher serum levels of tumour necrosis factor alpha (TNFa), a known myelosuppressive cytokine. In contrast, in a large study in patients with ischaemic or non-ischaemic HF, Michowitz et al. found a mild direct correlation between number of e-CFUs and NYHA class.<sup><xref ref-type="bibr" rid="bibr27-1470320312447650">27</xref></sup> Recently, novel evidence has been provided in patients with post-ischaemic HF indicating a selective functional exhaustion of the EPCs. Interestingly, bone marrow niches as well as the colony-forming capacity seemed to be reduced, whereas bone marrow haematopoietic progenitor cell number was preserved.<sup><xref ref-type="bibr" rid="bibr10-1470320312447650">10</xref></sup> One possible explanation could be the relation between a reduction in the bio-availability of nitric oxide (NO) in the bone marrow niches since NO has a pivotal role in modulating the activity of MMP-9 that is required for the mobilization of EPCs but also for the transfer of endothelial cells to a proliferative niche. Another explanation for conflicting results is the lack of a uniform EPC definition in different studies in the literature.</p>
<p>Several positive observations regarding a pharmaceutical modification of EPCs have been made. Especially, statins have been extensively tested and randomized trials exist confirming a positive effect in number and function in these cells among different patient populations, including patients with HF.<sup><xref ref-type="bibr" rid="bibr28-1470320312447650">28</xref></sup> Furthermore, ACE inhibitors and angiotensin II receptor blockers and oestrogen are understood to positively influence EPCs. Tousoulis et al. recently tested rosuvastatin and allopurinol treatment in patients with CHF and demonstrated a positive effect of rosuvastatin treatment, indicating that the treatment effect is independent of changes in inflammatory and oxidative status.<sup><xref ref-type="bibr" rid="bibr29-1470320312447650">29</xref></sup> In the current study no associations were detected to co-medications although different treatment regimes and dosages were used. Of interest is the positive association between EPCs and overweight, which has been described in adults without HF already.<sup><xref ref-type="bibr" rid="bibr30-1470320312447650">30</xref></sup> However, treatment effects on EPCs are thought to modulate the recruitment out of the bone marrow, apoptosis and functional capacity of these cells. As summarized above, survival and functional improvement of EPCs by blocking MR has been shown in-vitro already.</p>
<p>Our study has several limitations. First of all, the sample size is limited. Second, it is an observational study without randomization or adjustment to patient characteristics before initiation of eplerenone treatment. Therefore, we understand the current study as hypothesis generating suggesting a randomized placebo-controlled trial. However, our patient population is well characterized and represents a real-life scenario in an academic referral centre for CHF.</p>
<p>In conclusion, eplerenone treatment positively affects EPC numbers in patients with CHF, an effect that has been already described by in-vitro studies. The demonstrated benefit of eplerenone treatment might be mediated by this effect. Further studies are warranted to confirm these findings and to elucidate the exact underlying mechanisms.</p>
</sec>
</body>
<back>
<ack><p>We thank Annett Schmidt for excellent technical assistance.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320312447650">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urbich</surname><given-names>C</given-names></name>
<name><surname>Dimmeler</surname><given-names>S</given-names></name>
</person-group>. <article-title>Endothelial progenitor cells: Characterization and role in vascular biology</article-title>. <source>Circ Res</source> <year>2004</year>; <volume>95</volume>: <fpage>343</fpage>–<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr2-1470320312447650">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jujo</surname><given-names>K</given-names></name>
<name><surname>Ii</surname><given-names>M</given-names></name>
<name><surname>Losordo</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Endothelial progenitor cells in neovascularization of infarcted myocardium</article-title>. <source>J Mol Cell Cardiol</source> <year>2008</year>; <volume>45</volume>: <fpage>530</fpage>–<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr3-1470320312447650">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hill</surname><given-names>JM</given-names></name>
<name><surname>Zalos</surname><given-names>G</given-names></name>
<name><surname>Halcox</surname><given-names>JPJ</given-names></name>
<etal/>
</person-group>. <article-title>Circulating endothelial progenitor cells, vascular function, and cardiovascular risk</article-title>. <source>N Engl J Med</source> <year>2003</year>; <volume>348</volume>: <fpage>593</fpage>–<lpage>600</lpage>.</citation>
</ref>
<ref id="bibr4-1470320312447650">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt-Lucke</surname><given-names>C</given-names></name>
<name><surname>Rossig</surname><given-names>L</given-names></name>
<name><surname>Fichtlscherer</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair</article-title>. <source>Circulation</source> <year>2005</year>; <volume>111</volume>: <fpage>2981</fpage>–<lpage>2987</lpage>.</citation>
</ref>
<ref id="bibr5-1470320312447650">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Humpert</surname><given-names>PM</given-names></name>
<name><surname>Eichler</surname><given-names>H</given-names></name>
<name><surname>Lammert</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Adult vascular progenitor cells and tissue regeneration in metabolic syndrome</article-title>. <source>Vasa</source> <year>2005</year>; <volume>34</volume>: <fpage>73</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr6-1470320312447650">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Imanishi</surname><given-names>T</given-names></name>
<name><surname>Moriwaki</surname><given-names>C</given-names></name>
<name><surname>Hano</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension</article-title>. <source>J Hypertens</source> <year>2005</year>; <volume>23</volume>: <fpage>1831</fpage>–<lpage>1837</lpage>.</citation>
</ref>
<ref id="bibr7-1470320312447650">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>George</surname><given-names>J</given-names></name>
<name><surname>Herz</surname><given-names>I</given-names></name>
<name><surname>Goldstein</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2003</year>; <volume>23</volume>: <fpage>e57</fpage>–<lpage>e60</lpage>.</citation>
</ref>
<ref id="bibr8-1470320312447650">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jung</surname><given-names>C</given-names></name>
<name><surname>Rafnsson</surname><given-names>A</given-names></name>
<name><surname>Shemyakin</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Different subpopulations of endothelial progenitor cells and circulating apoptotic progenitor cells in patients with vascular disease and diabetes</article-title>. <source>Int J Cardiol</source> <year>2010</year>; <volume>3</volume>: <fpage>368</fpage>–<lpage>372</lpage>.</citation>
</ref>
<ref id="bibr9-1470320312447650">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>JZ</given-names></name>
<name><surname>Zhang</surname><given-names>FR</given-names></name>
<name><surname>Tao</surname><given-names>QM</given-names></name>
<etal/>
</person-group>. <article-title>Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia</article-title>. <source>Clin Sci (Lond)</source> <year>2004</year>; <volume>107</volume>: <fpage>273</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr10-1470320312447650">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kissel</surname><given-names>CK</given-names></name>
<name><surname>Lehmann</surname><given-names>R</given-names></name>
<name><surname>Assmus</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure</article-title>. <source>J Am Coll Cardiol</source> <year>2007</year>; <volume>49</volume>: <fpage>2341</fpage>–<lpage>2349</lpage>.</citation>
</ref>
<ref id="bibr11-1470320312447650">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nonaka-Sarukawa</surname><given-names>M</given-names></name>
<name><surname>Yamamoto</surname><given-names>K</given-names></name>
<name><surname>Aoki</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Circulating endothelial progenitor cells in congestive heart failure</article-title>. <source>Int J Cardiol</source> <year>2007</year>; <volume>119</volume>: <fpage>344</fpage>–<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr12-1470320312447650">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Valgimigli</surname><given-names>M</given-names></name>
<name><surname>Rigolin</surname><given-names>GM</given-names></name>
<name><surname>Fucili</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure</article-title>. <source>Circulation</source> <year>2004</year>; <volume>110</volume>: <fpage>1209</fpage>–<lpage>1212</lpage>.</citation>
</ref>
<ref id="bibr13-1470320312447650">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fritzenwanger</surname><given-names>M</given-names></name>
<name><surname>Lorenz</surname><given-names>F</given-names></name>
<name><surname>Jung</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure</article-title>. <source>European Journal of Medical Research</source> <year>2009</year>; <volume>14</volume>: <fpage>113</fpage>–<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr14-1470320312447650">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pelliccia</surname><given-names>F</given-names></name>
<name><surname>Pasceri</surname><given-names>V</given-names></name>
<name><surname>Cianfrocca</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Endothelial progenitor cells in patients with coronary artery disease and left ventricular dysfunction</article-title>. <source>Coron Artery Dis</source> <year>2009</year>; <volume>20</volume>: <fpage>303</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr15-1470320312447650">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schachinger</surname><given-names>V</given-names></name>
<name><surname>Assmus</surname><given-names>B</given-names></name>
<name><surname>Britten</surname><given-names>MB</given-names></name>
<etal/>
</person-group>. <article-title>Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: Final one-year results of the TOPCARE-AMI Trial</article-title>. <source>J Am Coll Cardiol</source> <year>2004</year>; <volume>44</volume>: <fpage>1690</fpage>–<lpage>1699</lpage>.</citation>
</ref>
<ref id="bibr16-1470320312447650">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Craenenbroeck</surname><given-names>EM</given-names></name>
<name><surname>Conraads</surname><given-names>VM</given-names></name>
</person-group>. <article-title>Endothelial progenitor cells in vascular health: Focus on lifestyle</article-title>. <source>Microvasc Res</source> <year>2010</year>; <volume>79</volume>: <fpage>184</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr17-1470320312447650">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pelliccia</surname><given-names>F</given-names></name>
<name><surname>Pasceri</surname><given-names>V</given-names></name>
<name><surname>Cianfrocca</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study</article-title>. <source>Atherosclerosis</source> <year>2010</year>; <volume>210</volume>: <fpage>510</fpage>–<lpage>515</lpage>.</citation>
</ref>
<ref id="bibr18-1470320312447650">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erbs</surname><given-names>S</given-names></name>
<name><surname>Beck</surname><given-names>EB</given-names></name>
<name><surname>Linke</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling – results from a randomized, double-blind, and placebo-controlled study</article-title>. <source>Int J Cardiol</source> <year>2011</year>; <volume>146</volume>: <fpage>56</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr19-1470320312447650">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thum</surname><given-names>T</given-names></name>
<name><surname>Schmitter</surname><given-names>K</given-names></name>
<name><surname>Fleissner</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>32</volume>: <fpage>1275</fpage>–<lpage>1286</lpage>.</citation>
</ref>
<ref id="bibr20-1470320312447650">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zannad</surname><given-names>F</given-names></name>
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
<name><surname>Krum</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Eplerenone in patients with systolic heart failure and mild symptoms</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>364</volume>: <fpage>11</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr21-1470320312447650">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ladage</surname><given-names>D</given-names></name>
<name><surname>Schutzeberg</surname><given-names>N</given-names></name>
<name><surname>Dartsch</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Hyperaldosteronism is associated with a decrease in number and altered growth factor expression of endothelial progenitor cells in rats</article-title>. <source>Int J Cardiol</source> <year>2011</year>; <volume>149</volume>: <fpage>152</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr22-1470320312447650">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fadini</surname><given-names>GP</given-names></name>
<name><surname>Miorin</surname><given-names>M</given-names></name>
<name><surname>Facco</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus</article-title>. <source>J Am Coll Cardiol</source> <year>2005</year>; <volume>45</volume>: <fpage>1449</fpage>–<lpage>1457</lpage>.</citation>
</ref>
<ref id="bibr23-1470320312447650">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jung</surname><given-names>C</given-names></name>
<name><surname>Fischer</surname><given-names>N</given-names></name>
<name><surname>Fritzenwanger</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Endothelial progenitor cells in adolescents: Impact of overweight, age, smoking, sport and cytokines in younger age</article-title>. <source>Clin Res Cardiol</source> <year>2009</year>; <volume>98</volume>: <fpage>179</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr24-1470320312447650">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Funder</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Reconsidering the roles of the mineralocorticoid receptor</article-title>. <source>Hypertension</source> <year>2009</year>; <volume>53</volume>: <fpage>286</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr25-1470320312447650">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iraqi</surname><given-names>W</given-names></name>
<name><surname>Rossignol</surname><given-names>P</given-names></name>
<name><surname>Angioi</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: Insights from the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study</article-title>. <source>Circulation</source> <year>2009</year>; <volume>119</volume>: <fpage>2471</fpage>–<lpage>2479</lpage>.</citation>
</ref>
<ref id="bibr26-1470320312447650">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>N</given-names></name>
<name><surname>Fukushima</surname><given-names>H</given-names></name>
<name><surname>Takeshima</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb</article-title>. <source>Am J Hypertens</source> <year>2010</year>; <volume>23</volume>: <fpage>1007</fpage>–<lpage>1013</lpage>.</citation>
</ref>
<ref id="bibr27-1470320312447650">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Michowitz</surname><given-names>Y</given-names></name>
<name><surname>Goldstein</surname><given-names>E</given-names></name>
<name><surname>Wexler</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure</article-title>. <source>Heart</source> <year>2007</year>; <volume>93</volume>: <fpage>1046</fpage>–<lpage>1050</lpage>.</citation>
</ref>
<ref id="bibr28-1470320312447650">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leone</surname><given-names>AM</given-names></name>
<name><surname>Valgimigli</surname><given-names>M</given-names></name>
<name><surname>Giannico</surname><given-names>MB</given-names></name>
<etal/>
</person-group>. <article-title>From bone marrow to the arterial wall: The ongoing tale of endothelial progenitor cells</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>890</fpage>–<lpage>899</lpage>.</citation>
</ref>
<ref id="bibr29-1470320312447650">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tousoulis</surname><given-names>D</given-names></name>
<name><surname>Andreou</surname><given-names>I</given-names></name>
<name><surname>Tsiatas</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress</article-title>. <source>Atherosclerosis</source> <year>2011</year>; <volume>214</volume>: <fpage>151</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr30-1470320312447650">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maceneaney</surname><given-names>OJ</given-names></name>
<name><surname>Kushner</surname><given-names>EJ</given-names></name>
<name><surname>Van Guilder</surname><given-names>GP</given-names></name>
<etal/>
</person-group>. <article-title>Endothelial progenitor cell number and colony-forming capacity in overweight and obese adults</article-title>. <source>Int J Obes (Lond)</source> <year>2009</year>; <volume>33</volume>: <fpage>219</fpage>–<lpage>225</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>